Last reviewed · How we verify
NCT05791929: MY-FOOT-B
LSCI and Thermography in Diabetic Foot Patients Affected by Ulcer(s): (MY-FOOT-B)
trial in Diabetes Mellitus, Type 2. Withdrawn.
10 October 2023
Quick facts
| Lead sponsor | Mario Negri Institute for Pharmacological Research |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 13 April 2023 |
| Primary completion | 10 October 2023 |
| Estimated completion | 4 December 2023 |
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
- Ulcer Foot — all drugs for Ulcer Foot →
Sponsor
Mario Negri Institute for Pharmacological Research
Who can join
Adults 18 to 80, any sex, with Diabetes Mellitus, Type 2 or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to predict healing at 26 weeks after the first visit in patients affected by the first ulcer, by means of combined data monitoring of Laser Speckle Contrast Imaging (LSCI) and temperature measurements during patient visits in hospital. In order to achieve this objective, study aims to produce a logistic regression model and then evaluate its prognostic ability by means of the area under the curve (AUC) of the receiver-operating-characteristics (ROC) curve. Patients with diabetes mellitus and suffering from ulcer and receiving health care will undergo regular microcirculatory measurements including LSCI scans in and around the ulcer location and thermography.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05791929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Mario Negri Institute for Pharmacological Research trials
Trials by the same sponsor.
- NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
- NCT07331103 — RESOLving INflammation Through Diet for Health (RESOLVIN) · NA · recruiting
- NCT06994468 — Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy · NA · completed
- NCT07111624 — A New Crowding Indicator in the Emergency Department · not yet recruiting
- NCT07021118 — Mild TBI in the Emergency Department · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05791929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mario Negri Institute for Pharmacological Research
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05791929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing